Alberto Berjón

Prof. Alberto Berjón

Hospital Universitario La Paz, Madrid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in EBioMedicine
Verified
Journal Article
Open access
LNLaura Nogués
Laura Nogués
CRClara Reglero
Clara Reglero
VRVerónica Rivas
Verónica Rivas
ASAlicia Salcedo
Alicia Salcedo
VLVanesa Lafarga
Vanesa Lafarga
Petronila PenelaPetronila Penela
Petronila Penela
In addition to oncogenic drivers, signaling nodes can critically modulate cancer-related cellular networks to strength tumor hallmarks. We identify G-protein-coupled receptor kinase 2 (GRK2) as a relevant player in breast cancer. GRK2 is up-regulated in breast cancer cell lines, in spontaneous tumors in mice, and in a proportion of invasive ductal carcinoma patients. Increased GRK2 functionality promotes the phosphorylation and activation of the Histone Deacetylase 6 (HDAC6) leading to de-acetylation of the Prolyl Isomerase Pin1, a central modulator of tumor progression, thereby enhancing its stability and functional interaction with key mitotic regulators. Interestingly, a correlation between GRK2 expression and Pin1 levels and de-acetylation status is detected in breast cancer patients. Activation of the HDAC6-Pin1 axis underlies the positive effects of GRK2 on promoting growth factor signaling, cellular proliferation and anchorage-independent growth in both luminal and basal breast cancer cells. Enhanced GRK2 levels promote tumor growth in mice, whereas GRK2 down-modulation sensitizes cells to therapeutic drugs and abrogates tumor formation. Our data suggest that GRK2 acts as an important onco-modulator by strengthening the functionality of key players in breast tumorigenesis such as HDAC6 and Pin1.

21 August 2021 in Virchows Archiv
Verified
Journal Article
Open access
PDF file
Ignacio Ruz-CaracuelIgnacio Ruz-Caracuel
Ignacio Ruz-Caracuel
ALAlvaro Lopez-Janeiro
Alvaro Lopez-Janeiro
VHVictoria Heredia
Victoria Heredia
JRJorge L. Ramón-Patino
Jorge L. Ramón-Patino
LYLaura Yébenes
Laura Yébenes
David HardissonDavid Hardisson
David Hardisson
Low-grade and early-stage endometrioid endometrial carcinomas (EECs) have an overall good prognosis but biomarkers identifying patients at risk of relapse are still lacking. Recently, CTNNB1 exon 3 mutation has been identified as a potential risk factor of recurrence in these patients. We evaluate the prognostic value of CTNNB1 mutation in a single-centre cohort of 218 low-grade, early-stage EECs, and the correlation with beta-catenin and LEF1 immunohistochemistry as candidate surrogate markers. CTNNB1 exon 3 hotspot mutations were evaluated by Sanger sequencing. Immunohistochemical staining of mismatch repair proteins (MLH1, PMS2, MSH2, and MSH6), p53, beta-catenin, and LEF1 was performed in representative tissue microarrays. Tumours were also reviewed for mucinous and squamous differentiation, and MELF pattern. Nineteen (8.7%) tumours harboured a mutation in CTNNB1 exon 3. Nuclear beta-catenin and LEF1 were significantly associated with CTNNB1 mutation, showing nuclear beta-catenin a better specificity and positive predictive value for CTNNB1 mutation. Tumours with CTNNB1 exon 3 mutation were associated with reduced disease-free survival (p = 0.010), but no impact on overall survival was found (p = 0.807). The risk of relapse in tumours with CTNNB1 exon 3 mutation was independent of FIGO stage, tumour grade, mismatch repair protein expression, or the presence of lymphovascular space invasion. CTNNB1 exon 3 mutation has a negative impact on disease-free survival in low-grade, early-stage EECs. Nuclear beta-catenin shows a higher positive predictive value than LEF1 for CTNNB1 exon 3 mutation in these tumours. Graphical abstract

14 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ÁLÁlvaro López-Janeiro
Álvaro López-Janeiro
Ignacio Ruz-CaracuelIgnacio Ruz-Caracuel
Ignacio Ruz-Caracuel
JRJorge L Ramon-Patino
Jorge L Ramon-Patino
VRVivian De Los Ríos
Vivian De Los Ríos
MVMaría Villalba
María Villalba
David HardissonDavid Hardisson
David Hardisson
Low-grade, early-stage endometrial carcinoma (EC) is the most frequent malignant tumor of the uterine corpus. However, the molecular alterations that underlie these tumors are far from being fully understood. The purpose of this study is to describe dysregulated molecular pathways from EC patients. Sixteen samples of tumor tissue and paired healthy controls were collected and both were subjected to mass spectrometry (MS)/MS proteomic analysis. Gene ontology and pathway analysis was performed to discover dysregulated pathways and/or proteins using different databases and bioinformatic tools. Dysregulated pathways were cross-validated in an independent external cohort. Cell signaling, immune response, and cell death-associated pathways were robustly identified. The SLIT/ROBO signaling pathway demonstrated dysregulation at the proteomic and transcriptomic level. Necroptosis and ferroptosis were cell death-associated processes aberrantly regulated, in addition to apoptosis. Immune response-associated pathways showed a dominance of innate immune responses. Tumor immune infiltrates measured by immunofluorescence demonstrated diverse lymphoid and myeloid populations. Our results suggest a role of SLIT/ROBO, necroptosis, and ferroptosis, as well as a prominent role of innate immune response in low-grade, early-stage EC. These results could guide future research in this group of tumors.

1 October 2016 in Gynecologic Oncology
Verified
Journal Article
Closed access
MLMaría E. López-Ruiz
María E. López-Ruiz
MDMaría D. Diestro
María D. Diestro
LYLaura Yébenes
Laura Yébenes
ABAlberto Berjón
Alberto Berjón
Begoña Díaz de-la-NovalBegoña Díaz de-la-Noval
Begoña Díaz de-la-Noval
David HardissonDavid Hardisson
David Hardisson

1 February 2022 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
MMMarta Mendiola
Marta Mendiola
TPTeijo Pellinen
Teijo Pellinen
JRJorge L. Ramon-Patino
Jorge L. Ramon-Patino
ABAlberto Berjón
Alberto Berjón
OBOscar Brück
Oscar Brück
ARAndres Redondo
Andres Redondo

24 April 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
VHVictoria Heredia-Soto
Victoria Heredia-Soto
ARAndres Redondo
Andres Redondo
ABAlberto Berjón
Alberto Berjón
MMMaría Miguel-Martín
María Miguel-Martín
EDEsther Díaz
Esther Díaz
MMMarta Mendiola
Marta Mendiola
High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease